Quince Therapeutics Financials - Benzinga

Quince Therapeutics Inc

QNCXNASDAQ

Trade with Public

Trade with Public

$33.03

0.461.41%

Last update: Sep 1, 9:30 AM

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Options Stock Report

Quince Therapeutics Financials

Quince Therapeutics (QNCX) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Quince Therapeutics Q2 EPS $(12.31) Beats $(26.32) Estimate

Quince Therapeutics (NASDAQ:QNCX) reported quarterly losses of $(12.31) per share which beat the analyst consensus estimate of $(26.32) by 53.21 percent. This is a 81.9 percent increase over losses of $(68.00) per share

Benzinga Newsdesk

Gold Moves Lower; CVS Health Earnings Top Views

Avi Kapoor

PRO
Quince Therapeutics Q3 EPS $(0.25) Misses $(0.21) Estimate

Benzinga Newsdesk

PRO
Quince Therapeutics Q2 EPS $(0.34) Misses $(0.26) Estimate

Quince Therapeutics (NASDAQ:QNCX) reported quarterly losses of $(0.34) per share which missed the analyst consensus estimate of $(0.26) by 30.77 percent. This is a 46.88 percent increase over losses of $(0.64) per share

Benzinga Newsdesk

PRO
Quince Therapeutics Q3 EPS $(0.13) Up From $(0.15) YoY

Quince Therapeutics (NASDAQ:QNCX) reported quarterly losses of $(0.13) per share. This is a 13.33 percent increase over losses of $(0.15) per share from the same period last year.

Benzinga Newsdesk

PRO
Quince Therapeutics Q2 EPS $(0.64) Down From $(0.14) YoY

Quince Therapeutics (NASDAQ: QNCX) reported quarterly losses of $(0.64) per share. This is a 357.14 percent decrease over losses of $(0.14) per share from the same period last year.

Benzinga Newsdesk